Industries Study Report: Cancer Diagnostics Industry

Showing posts with label Cancer Diagnostics Industry. Show all posts

Unlocking the Potential: The Latest Innovations in Cancer Diagnostics Industry

Cancer Diagnostics Industry Data Book - Breast Cancer Diagnostic, Cervical Cancer Diagnostic, Lung Cancer Diagnostic, Liver Cancer Diagnostic, Pancreatic Cancer Diagnostic and Ovarian Cancer Diagnostic Market Size, Share, Trends Analysis, and Segment Forecasts, 2023 - 2030

The global Cancer Diagnostics Industry was estimated at USD 45.66 billion in 2022 and is expanding at significant CAGR of 5.9% from 2023 to 2030, according to a new report by Grand View Research, Inc.

Grand View Research’s cancer diagnostics industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.

Access the Global Cancer Diagnostics Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies

Cervical Cancer Diagnostics Market Growth & Trends

The global cervical cancer diagnostic market size is expected to reach USD 7.0 billion by 2030, growing at a CAGR of 5.65% from 2023 to 2030, according to a new study conducted by Grand View Research, Inc. The key driving factors include the rising prevalence of cervical cancer, evolving screening technology, and various programs that promote routine check up and screening. According to the data published by the WHO, in 2012, over 270,000 women died due to cervical cancer, majority of which were from the developing countries. It is one of the most common cancer type diagnosed in women. Some of the etiological factors are multiple sex partners, and changing lifestyle, such as drinking & smoking and increased stress levels.

Furthermore, favorable government initiatives and increasing number of awareness programs are further expected to promote the market growth in coming few years. The National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, are working towards promoting the necessity for early screening of cervical cancer amongst mid aged women.

There is an increasing demand for technologically advanced diagnostic procedures that facilitate the early intervention of the disease. The industry players are focused on developing innovative technological solutions for accurate and efficient results. Advancement in screening techniques, such as use of biomarkers, is gaining importance. The upsurge in technological developments is anticipated to further drive industry growth.

Order your copy of the Free Sample of “Cancer Diagnostics Industry Data Book - Breast Cancer Diagnostic, Cervical Cancer Diagnostic, Lung Cancer Diagnostic, Liver Cancer Diagnostic, Pancreatic Cancer Diagnostic and Ovarian Cancer Diagnostic Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Breast Cancer Diagnostics Market Growth & Trends

The global breast cancer diagnostics market size is expected to reach USD 7.7 billion by 2030, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 7.24% from 2023 to 2030. The growth is largely attributable to the increasing geriatric population exposed to the risk of breast cancer and early detection coupled with increasing awareness about breast cancer.

The introduction of 3D mammography or digital breast tomosynthesis, which is more accurate than 2D mammography, supports market growth. This advanced technology can detect 40.0% more cancers than 2D mammograms and reduce patient recalls. Rapid technological advancements are a major factor expected to drive the market over the coming years.

Companies are adopting strategies that allow them to use their resources to aid in the development of new products, as well as enhance their supply chain. In November 2019, Exact Sciences Corporation announced the acquisition of Genomic Health, which was expected to help enhance the company’s market position and offerings by acquiring its product portfolio. In January 2021, Hologic Inc. announced that it has agreed to acquire Biotheranostics for approximately US$ 230 million. Biotheranostics is a commercial-stage molecular diagnostics provider for breast and metastatic cancers.

Go through the table of content of Cancer Diagnostics Industry Data Book to get a better understanding of the Coverage & Scope of the study

Competitive Landscape

Key players operating in the Cancer Diagnostics industry are:

Hoffmann-La Roche Ltd.
GE Healthcare
Abbott
Illumina, Inc.
Qiagen N.V.

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com/sector-reports-list
Follow Us: LinkedIn | Twitter

Cancer Diagnostics Industry: List of Key Emerging Companies, Technology Disruptors, and Innovators

Access the Global Cancer Diagnostics Industry Data Book, 2023 to 2030, compiled with details like trade data, pricing intelligence, and competitive benchmarking.

Breast Cancer Market Report Highlights

The global Breast Cancer Market size was valued at USD 16.26 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.24% from 2023 to 2030.

The imaging segment held the largest revenue share in 2022 and the blood tests segment is expected to grow at the fastest rate
By product, the instrument-based products segment accounted for the largest revenue share in 2022 due to government initiatives such as mandatory screening in developed countries such as the U.S., Canada, and the U.K. for women above 45 years of age, increasing the overall testing and screening of breast cancer
The platform-based products segment is expected to witness the fastest growth over the forecast period. These tests are mostly used for assessing the efficacy of chemotherapy and targeted therapy in women
By application, the diagnostic and predictive segment dominated the market in 2022 and the prognostic segment is expected to witness the fastest CAGR over the forecast period due to increasing collaborations and efforts for advancements in diagnostics
The hospitals and clinics segment dominated the market in 2022
The medical labs and diagnostics centers segment is expected to witness the fastest CAGR over the forecast period due to an increase in platform-based testing such as NGS, and PCR

Breast Cancer Diagnostic Market Share, by End-Use, 2022 (%)

Order your copy of Free Sample of “Cancer Diagnostics Industry Data Book - Breast Cancer Diagnostic, Cervical Cancer Diagnostic, Lung Cancer Diagnostic, Liver Cancer Diagnostic, Pancreatic Cancer Diagnostic and Ovarian Cancer Diagnostic Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Lung Cancer Market Report Highlights

The global Lung Cancer Market size was valued at USD 10.82 billion in 2022 and is expected to grow at compound annual growth rate (CAGR) of 7.59% from 2023 to 2030.

The small cell lung cancer segment accounted for around 15% market share in 2015. This is an aggressive subtype of the lung malignancies, which has proven to be fatal within a short period of time if left undiagnosed.
Non-small cell lung cancer was identified as the largest segment in 2015 with revenue of over USD 1,300.0 million. This is majorly due to the availability of novel lung cancer diagnostics that facilitate the detection of large tumor growths.
The imaging tests segment was identified as the largest revenue generating segment in 2015 with a market share of around 50%. Major factors responsible for the large market share include the frequent use of various imaging techniques such as CT scan, X-ray, and MRI in the detection of lung malignancies coupled with the increased availability of the diagnostic tools.
The molecular testing segment is expected to grow at a profitable rate of around 10% over the forecast period. The introduction of novel molecular testing techniques coupled with the increasing number of investments to support the research and development efforts for the development of biomarker-based molecular testing in lung cancer detection is expected to foster the demand of this segment over the forecast period.
In 2015, North America accounted for the largest revenue share of over 30% majorly due to supportive government policies in the region coupled with the availability of technology-enabled lung cancer diagnostics
Asia Pacific region is expected to reach a revenue share of over 28% by 2024. Major factors responsible for the growth include the constantly improving healthcare infrastructure, the growing awareness of the disease symptoms, and a wide base of unmet clinical needs in the developing countries in the region.

Go through the table of content of Cancer Diagnostics Industry Data Book to get a better understanding of the Coverage and Scope of the study

Competitive Landscape

Key players in this market are implementing various strategies including partnerships, mergers and acquisitions, geographical expansion, and strategic collaborations to expand their market presence. For instance, in February 2023, F. Hoffmann-La Roche Ltd. announced extending its collaboration with Janssen to advance personalized healthcare by focusing on companion diagnostics.

Key players operating in the Cancer Diagnostics Industry are:

Siemens Healthcare GmbH
Thermo Fisher Scientific, Inc.
Hologic, Inc.
Koninklijke Philips N.V. (Philips)
BD

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Contact:

Cancer Diagnostics Industry: Cervical Cancer Diagnostics Market to outshine 5.65% CAGR, 2023-2030

Cancer Diagnostics Industry Data Book Covers Breast Cancer Diagnostic, Cervical Cancer Diagnostic, Lung Cancer Diagnostic, Liver Cancer Diagnostic, Pancreatic Cancer Diagnostic, and Ovarian Cancer Diagnostic Market

The global Cancer Diagnostics Industry was estimated at USD 45.66 billion in 2022 and is anticipated to increase at a significant CAGR of 5.9% from 2023 to 2030.

Liver Cancer Diagnostics Market Insights

The global liver cancer diagnostics market size was valued at USD 5.99 billion in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 5.96% by 2030. Around the world, liver cancer is among the leading cause of cancer-related deaths. As per the American Cancer Society, since the 1980s, liver cancer occurrence rates have increased three times and death rates have doubled now. According to cancer statistics in 2022, in the U.S., around 41,260 new cases are expected to be diagnosed whereas about 30,520 deaths will account because of liver cancer. The prevalence of liver cancer worldwide and the associated continuous exposure of the population to risk factors will drive the screening & diagnosis market rapidly.

The risk factors for liver cancer include lifestyle changes such as smoking, alcohol consumption, and tobacco chewing, and diseases such as chronic viral hepatitis i.e. hepatitis B virus (HBV) or hepatitis C virus (HCV), cirrhosis, type 2 diabetes, and even obesity. The prevalence of one or more risk factors predisposes the liver and increases the probability of the occurrence of liver cancer. Accurate early detection, diagnosis & staging is important for improving survival rates. This has led to exhaustive initiatives undertaken by many institutes & companies to develop innovative solutions for screening. For example, in October 2022, researchers using the DELFI platform, an AI liquid biopsy technology by Delfi Diagnostics, Inc. presented the findings of accuracy in the detection of patients with liver cancer from patients without cancer, in a cost-effective manner.

Moreover, the growing number of government programs to spread awareness about early detection & diagnosis of liver cancer will also boost the worldwide demand for diagnostics solutions. For instance, in August 2022, the National Cancer Institute (NCI) sponsored researchers from Baylor College of Medicine, Texas with USD 5.5 million in a 5-year grant. The research will have a goal to reduce the burden of liver cancer by analyzing the risk factors, and identification of preventative treatments. Also, collaborative efforts and partnerships by the WHO, National Cervical Cancer Coalition, the U.S. Preventive Services Task Force, the CDC, and others for routine screening programs for liver cancers are key factors anticipated to fuel the growth during the forecast years.

Multiparameter Patient Monitoring System Market size (USD Million), 2022 & 2030, & Market Attributes

Pancreatic Cancer Diagnostic Market Insights

The global pancreatic cancer diagnostic market size was valued at USD 2.37 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.53% from 2023 to 2030. The increasing prevalence of pancreatic cancer and the rise in awareness regarding early disease diagnosis is the leading factor driving the global market. In addition, technological advancements in terms of accuracy & sensitivity of diagnostic tests, evolution in molecular diagnostics, and biomarker tests used for malignancy detection are other factors propelling the market demand forward.

Pancreatic cancer is one of the leading causes of cancer-related deaths globally and the burden of disease is escalating at a significant pace. According to the American Cancer Society, the 5-year relative survival rate of patients having localized pancreatic cancer is around 44%, whereas, in the case of regional and distant stages, the 5-year relative survival rate is 15% and 3% respectively. Therefore, medical professionals and healthcare authorities are emphasizing developing & commercializing precise screening methods to monitor the prevalence levels.

Moreover, early disease diagnosis is very crucial for positive treatment outcomes. As a result, market players and healthcare organizations are raising funds, awareness programs, and research initiatives to promote routine checkups and screenings. For instance, in August 2022, the Pancreatic Cancer Action Network (PanCAN) awarded USD 10.5 million for 16 new grants that would support R&D activities for early detection and better treatment options in cases of pancreatic cancer.

The significant rise in the number of pancreatic malignancy cases is fueling the adoption of screening tests and creating a demand for novel screening tests. According to the National Cancer Institute, in 2022, the number of estimated new cases was 62,210, with 49,830 deaths in the U.S. Currently, diagnostic tests like biomarker tests, liver function tests, biopsies, imaging tests, and others are used in disease diagnosis.

Go through the table of content of Cancer Diagnostics Industry Data Book to get a better understanding of the Coverage & Scope of the study

Cancer Diagnostics Industry Data Book Competitive Landscape

Key players operating in the Cancer Diagnostics Industry are:

GE Healthcare
Abbott
Hoffmann-La Roche Ltd.,
QIAGEN
BD

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Contact:

Unlocking the Potential: The Latest Innovations in Cancer Diagnostics Industry

Cancer Diagnostics Industry: List of Key Emerging Companies, Technology Disruptors, and Innovators

Cancer Diagnostics Industry: Cervical Cancer Diagnostics Market to outshine 5.65% CAGR, 2023-2030

Feeding the Blue Revolution: The Aquafeed Market Takes Center Stage